J Cardiovasc Imaging.  2018 Jun;26(2):45-53. 10.4250/jcvi.2018.26.e9.

Antihypertensive Treatment in Severe Aortic Stenosis

• Kang TS
• Park S

• KMID: 2415451
• DOI: http://doi.org/10.4250/jcvi.2018.26.e9

Abstract

Previously, antihypertensive treatment in severe aortic stenosis was considered a relative contraindication. However, recent studies have shown that antihypertensive treatment may be safe and even beneficial in terms of reducing the progression of left ventricular pressure overload and even retarding the progression of valvular aortic stenosis. To date, no randomized clinical trials have been performed and no definite treatment guideline exist for the proper antihypertensive regimens. Antihypertensive treatment with β-blockers has generally been avoided in patients with severe aortic stenosis (AS) due to the concerns for inducing left ventricular dysfunction and hemodynamic compromise in the presence of severe outflow tract obstruction. Although it remains unclear whether antihypertensive treatment with a β-blocker is associated with increased risk of cardiovascular events in patients with AS, recent studies have shown that the use of β-blockers may be safe and may even be beneficial. Renin-angiotensin system (RAS) are upregulated in AS and have been shown to be involved in valve calcification and progression in both experimental models and in human trials. As such, theoretically, RAS inhibition would have benefit in retarding the progression of valvular stenosis as well as have benefit in left ventricle remodeling. Recent clinical studies are indeed showing that use of RAS inhibition may be beneficial in patients with AS. Future clinical trials to establish the ideal target blood pressure and antihypertensive regimens in severe AS is essential.

Keyword

Aortic valve stenosis; Antihypertensive treatment; Aortic valve replacement

MeSH Terms

Aortic Valve Stenosis*
Blood Pressure
Constriction, Pathologic
Hemodynamics
Humans
Models, Theoretical
Renin-Angiotensin System
Ventricular Dysfunction, Left
Ventricular Pressure
Ventricular Remodeling

Figure

• 

  Figure 1 Algorithm of antihypertensive treatment of severe aortic stenosis. AR: aortic regurgitation, BP: blood pressure, RAS: renin-angiotensin system.

Reference

1. Mozaffarian D, Benjamin EJ, Go AS, American Heart Association Statistics Committee; Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016; 133:e38–e360.

2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368:1005–1011.

3. Rossebø AB, Pedersen TR, Boman K, SEAS Investigators, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359:1343–1356.

4. Tastet L, Capoulade R, Clavel MA, et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study. Eur Heart J Cardiovasc Imaging. 2017; 18:70–78.

5. Cramariuc D, Cioffi G, Rieck AE, et al. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovasc Imaging. 2009; 2:390–399.

6. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005; 46:291–298.

7. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol. 2009; 54:1003–1011.

8. Nishimura RA, Otto CM, Bonow RO, ACC/AHA Task Force Members, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129:e521–e643.

9. Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circ Res. 2013; 113:223–237.

10. Marquis-Gravel G, Redfors B, Leon MB, Généreux P. Medical treatment of aortic stenosis. Circulation. 2016; 134:1766–1784.

11. Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS). Circulation. 2016; 134:455–468.

12. Iwata S, Russo C, Jin Z, et al. Higher ambulatory blood pressure is associated with aortic valve calcification in the elderly: a population-based study. Hypertension. 2013; 61:55–60.

13. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg. 2006; 82:2116–2122.

14. Ngo DT, Stafford I, Sverdlov AL, et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol. 2011; 162:722–732.

15. O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005; 165:858–862.

16. Bang CN, Greve AM, Køber L, et al. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int J Cardiol. 2014; 175:492–498.

17. Chockalingam A, Venkatesan S, Subramaniam T, Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J. 2004; 147:E19.

18. Dalsgaard M, Iversen K, Kjaergaard J, et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. Am Heart J. 2014; 167:226–234.

19. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015; 16:834–841.

20. Capoulade R, Clavel MA, Mathieu P, et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest. 2013; 43:1262–1272.

21. Bang CN, Greve AM, Rossebø AB, et al. Antihypertensive treatment with β-blockade in patients with asymptomatic aortic stenosis and association with cardiovascular events. J Am Heart Assoc. 2017; 6:e006709.

22. Rossi A, Temporelli PL, Cicoira M, et al. Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis. Int J Cardiol. 2015; 190:15–17.

23. Hansson NH, Sörensen J, Harms HJ, et al. Metoprolol reduces hemodynamic and metabolic overload in asymptomatic aortic valve stenosis patients: a randomized trial. Circ Cardiovasc Imaging. 2017; 10:e006557.

24. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71:e127–e248.

25. Broch K, Urheim S, Lønnebakken MT, et al. Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. Heart. 2016; 102:191–197.

26. Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003; 348:1756–1763.

27. Eleid MF, Nishimura RA, Sorajja P, Borlaug BA. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction. Circulation. 2013; 128:1349–1353.

28. Little SH, Chan KL, Burwash IG. Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. Heart. 2007; 93:848–855.

29. Lloyd JW, Nishimura RA, Borlaug BA, Eleid MF. Hemodynamic response to nitroprusside in patients with low-gradient severe aortic stenosis and preserved ejection fraction. J Am Coll Cardiol. 2017; 70:1339–1348.

30. Mack MJ, Leon MB, Smith CR, PARTNER 1 trial investigators, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015; 385:2477–2484.

31. Douglas PS, Hahn RT, Pibarot P, et al. Hemodynamic outcomes of transcatheter aortic valve replacement and medical management in severe, inoperable aortic stenosis: a longitudinal echocardiographic study of cohort B of the PARTNER trial. J Am Soc Echocardiogr. 2015; 28:210–217.e1-9.

32. Perlman GY, Loncar S, Pollak A, et al. Post-procedural hypertension following transcatheter aortic valve implantation: incidence and clinical significance. JACC Cardiovasc Interv. 2013; 6:472–478.

33. Dahl JS, Videbaek L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol. 2010; 106:713–719.

34. Goel SS, Aksoy O, Gupta S, et al. Renin-angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study. Ann Intern Med. 2014; 161:699–710.